Maze Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

South San Francisco, CA – Maze Therapeutics, Inc. (NASDAQ: MAZE), a leading company in the development of novel genetic medicines, has announced the results of its 2026 Annual Meeting of Stockholders, held virtually on June 8, 2026.

Key Highlights from the Annual Meeting

• Strong Shareholder Turnout: A total of 44,660,029 shares of common stock, representing approximately 89.75% of the total outstanding shares entitled to vote, were present virtually or represented by proxy. This high turnout ensured a quorum and demonstrates significant shareholder engagement.
• Election of Directors: Stockholders voted on the election of two Class I directors, Jason Coloma, Ph.D., and Neil Kumar, Ph.D., to serve until the 2029 annual meeting or until their successors are duly elected and qualified.
  • Jason Coloma, Ph.D.:
    • Votes For: 35,792,536
    • Votes Against: 5,926,467
    • Broker Non-Votes: 2,941,026
  • Neil Kumar, Ph.D.:
    • Votes For: 34,056,425
    • Votes Against: 7,662,578
    • Broker Non-Votes: 2,941,026
  • Both director nominees were elected by a comfortable margin, indicating continued shareholder confidence in the company’s leadership and strategic direction.
• Ratification of Independent Auditor: The appointment of Ernst & Young LLP as Maze Therapeutics’ independent registered public accounting firm for the year ending December 31, 2026, was overwhelmingly ratified.
  • Votes For: 44,557,778
  • Votes Against: 728
  • Abstentions: 101,523
  • Broker Non-Votes: 0

  This near-unanimous approval reflects broad trust in the company’s financial oversight and audit practices.

Additional Information for Shareholders

• Emerging Growth Company Status: The company continues to qualify as an emerging growth company under the relevant SEC rules, and has not elected to opt out of the extended transition period for complying with new or revised accounting standards. This status may provide Maze Therapeutics with certain regulatory and financial reporting advantages.
• Corporate Information:
  • Principal Office: 171 Oyster Point Boulevard, Suite 300, South San Francisco, CA 94080
  • Phone: 650-850-5070
  • Incorporated in Delaware
  • Trading Symbol: MAZE
  • Exchange: The Nasdaq Stock Market LLC
  • Common Stock – par value \$0.001 per share

Potential Impact on Share Value

The successful election of directors and the strong ratification of the independent auditor signal investor confidence in the company’s management and governance. The high quorum and clear voting results suggest alignment between management and shareholders, which can be seen as positive for the company’s strategic stability and transparency. However, no new corporate actions or material events were announced that would directly impact the company’s operational or financial outlook. As such, while the results reinforce stability and trust, they may not in themselves be a catalyst for significant share price movement in the immediate term unless accompanied by future business developments.

Conclusion

Maze Therapeutics, Inc. remains committed to strong governance and transparent reporting, as reflected in the outcome of its 2026 Annual Meeting. Investors should continue to monitor the company for future strategic initiatives, pipeline updates, and other potential catalysts that could impact shareholder value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult with a financial advisor before making investment decisions. The information is based on the company’s public filings as of June 2026 and may be subject to change.

View Maze Therapeutics, Inc. Historical chart here